Technical Analysis for REVB - Revelation Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -2.09% | |
| Calm After Storm | Range Contraction | -2.09% | |
| Wide Bands | Range Expansion | -2.09% | |
| Gapped Up | Strength | -2.09% | |
| Oversold Stochastic | Weakness | -2.09% |
| Alert | Time |
|---|---|
| Down 5% | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Up 3% | about 9 hours ago |
| Fell Below Lower Bollinger Band | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/09/2024
Revelation Biosciences, Inc. Description
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Disease Immunology Infection Vaccination Respiratory Diseases Allergology Nasal Administration Rhinitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.8 |
| 52 Week Low | 1.61 |
| Average Volume | 760,848 |
| 200-Day Moving Average | 9.72 |
| 50-Day Moving Average | 2.08 |
| 20-Day Moving Average | 2.14 |
| 10-Day Moving Average | 2.10 |
| Average True Range | 0.32 |
| RSI (14) | 41.52 |
| ADX | 24.32 |
| +DI | 33.95 |
| -DI | 17.66 |
| Chandelier Exit (Long, 3 ATRs) | 2.85 |
| Chandelier Exit (Short, 3 ATRs) | 2.56 |
| Upper Bollinger Bands | 2.48 |
| Lower Bollinger Band | 1.81 |
| Percent B (%b) | 0.09 |
| BandWidth | 31.00 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0397 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.22 | ||||
| Resistance 3 (R3) | 2.22 | 2.11 | 2.16 | ||
| Resistance 2 (R2) | 2.11 | 2.02 | 2.11 | 2.14 | |
| Resistance 1 (R1) | 1.99 | 1.97 | 1.94 | 1.99 | 2.12 |
| Pivot Point | 1.88 | 1.88 | 1.85 | 1.88 | 1.88 |
| Support 1 (S1) | 1.76 | 1.79 | 1.71 | 1.76 | 1.62 |
| Support 2 (S2) | 1.65 | 1.74 | 1.65 | 1.60 | |
| Support 3 (S3) | 1.53 | 1.65 | 1.58 | ||
| Support 4 (S4) | 1.53 |
